Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) EBITDA (2019 - 2025)

Goldenwell Biotech (GWLL) has disclosed EBITDA for 7 consecutive years, with -$5885.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 74.49% year-over-year to -$5885.0, compared with a TTM value of $30883.0 through Sep 2025, up 125.16%, and an annual FY2024 reading of -$27597.0, up 76.17% over the prior year.
  • EBITDA was -$5885.0 for Q3 2025 at Goldenwell Biotech, down from -$3120.0 in the prior quarter.
  • Across five years, EBITDA topped out at $72165.0 in Q4 2024 and bottomed at -$920334.0 in Q4 2022.
  • Average EBITDA over 5 years is -$67903.3, with a median of -$27084.0 recorded in 2023.
  • Peak annual rise in EBITDA hit 17230.14% in 2021, while the deepest fall reached 15940.48% in 2021.
  • Year by year, EBITDA stood at -$100253.0 in 2021, then crashed by 818.01% to -$920334.0 in 2022, then surged by 97.74% to -$20799.0 in 2023, then soared by 446.96% to $72165.0 in 2024, then crashed by 108.15% to -$5885.0 in 2025.
  • Business Quant data shows EBITDA for GWLL at -$5885.0 in Q3 2025, -$3120.0 in Q2 2025, and -$32277.0 in Q1 2025.